Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Chen YC, Chuang CH, Miao ZF, Yip KL, Liu CJ, Li LH, Wu DC, Cheng TL, Lin CY, Wang JY
Journal
Frontiers in oncology
Year
2022
Keywords:
Bifidobacterium species, Fusobacterium nucleatum, Klebsiella quasipneumoniae, Lactobacillus species, metastatic colorectal cancer, targeted therapy
Studies have reported the effects of the gut microbiota on colorectal cancer (CRC) chemotherapy, but few studies have investigated the association between gut microbiota and targeted therapy. This study investigated the role of the gut microbiota in the treatment outcomes of patients with metastatic CRC (mCRC). We enrolled 110 patients with mCRC and treated them with standard cancer therapy. Stool samples were collected before administering a combination of chemotherapy and targeted therapy. Patients who had a progressive disease (PD) or partial response (PR) for at least 12 cycles of therapy were included in the study. We further divided these patients into anti-epidermal growth factor receptor (cetuximab) and anti-vascular endothelial growth factor (bevacizumab) subgroups. The gut microbiota of the PR group and bevacizumab-PR subgroup exhibited significantly higher α-diversity. The β-diversity of bacterial species significantly differed between the bevacizumab-PR and bevacizumab-PD groups (P = 0.029). Klebsiella quasipneumoniae exhibited the greatest fold change in abundance in the PD group than in the PR group. Lactobacillus and Bifidobacterium species exhibited higher abundance in the PD group. The abundance of Fusobacterium nucleatum was approximately 32 times higher in the PD group than in the PR group. A higher gut microbiota diversity was associated with more favorable treatment outcomes in the patients with mCRC. Bacterial species analysis of stool samples yielded heterogenous results. K. quasipneumoniae exhibited the greatest fold change in abundance among all bacterial species in the PD group. This result warrants further investigation especially in a Taiwanese population.
Experiment 1
Reviewed Marked as Reviewed by Svetlana up on 2025-3-26
Subjects
- Location of subjects
- Taiwan
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Metastatic colorectal cancer Metastatic colorectal cancer,metastatic colorectal cancer
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Partial response group- PR
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Progressive disease group- PD
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients who had a progressive disease (PD) for at least 12 cycles of therapy
- Group 0 sample size Number of subjects in the control (unexposed) group
- 31
- Group 1 sample size Number of subjects in the case (exposed) group
- 24
Lab analysis
- Sequencing type
- WMS
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- raw counts
- Statistical test
- DESeq2
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-3-26
Source: Figure 4A
Description: Results of the log2 fold change in the disease progression and partial response groups
Abundance in Group 1: increased abundance in Progressive disease group- PD
Revision editor(s): Miss Lulu
Signature 2
Reviewed Marked as Reviewed by Svetlana up on 2025-3-26
Source: Figure 4A
Description: Results of the log2 fold change in the disease progression and partial response groups
Abundance in Group 1: decreased abundance in Progressive disease group- PD
Revision editor(s): Miss Lulu
Experiment 2
Reviewed Marked as Reviewed by Svetlana up on 2025-3-26
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Bevacizumab-PR subgroup
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Bevacizumab-PD subgroup
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with progressive disease (PD) who had anti-vascular endothelial growth factor (bevacizumab) subgroups.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 17
- Group 1 sample size Number of subjects in the case (exposed) group
- 18
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-3-26
Source: Figure 4B
Description: Results of the log2 fold change in the subgroups of bevacizumab
Abundance in Group 1: increased abundance in Bevacizumab-PD subgroup
Revision editor(s): Miss Lulu
Signature 2
Reviewed Marked as Reviewed by Svetlana up on 2025-3-26
Source: Figure 4B
Description: Results of the log2 fold change in the subgroups of bevacizumab
Abundance in Group 1: decreased abundance in Bevacizumab-PD subgroup
| NCBI | Quality Control | Links |
|---|---|---|
| Segatella copri | ||
| Prevotella dentalis | ||
| Phocaeicola coprophilus |
Revision editor(s): Miss Lulu
Experiment 3
Reviewed Marked as Reviewed by Svetlana up on 2025-3-26
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Cetuximab-PR subgroup
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Cetuximab-PD subgroup
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with progressive disease (PD) who had anti-epidermal growth factor receptor (cetuximab) subgroups.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 14
- Group 1 sample size Number of subjects in the case (exposed) group
- 6
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-3-26
Source: Figure 4C
Description: Results of the log2 fold change in the subgroups of cetuximab
Abundance in Group 1: increased abundance in Cetuximab-PD subgroup
| NCBI | Quality Control | Links |
|---|---|---|
| Anaerostipes caccae | ||
| Adlercreutzia equolifaciens |
Revision editor(s): Miss Lulu
Retrieved from "https://bugsigdb.org/w/index.php?title=36212420&oldid=192060"
